Ignite Creation Date:
2025-12-25 @ 2:45 AM
Ignite Modification Date:
2025-12-31 @ 1:45 AM
Study NCT ID:
NCT01624233
Status:
COMPLETED
Last Update Posted:
2019-09-10
First Post:
2012-06-18
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
UNCOVER-J
Brief Summary:
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I1F-JE-RHAT | OTHER | Eli Lilly and Company | View |